Healthcare marketing has constraints that horizontal AI CMO content ignores: HIPAA, FDA promotional rules, off-label discussion restrictions, and the compliance review layer that exists in no other vertical. Most generic AI CMO advice fails in healthcare for one or more of these reasons. This is the healthcare-specific guide.
Healthcare marketing teams should default to AI CMO tooling for internal-facing work (research, planning, draft generation) and add a compliance review layer before anything customer-facing ships. Dedicated AI CMO products (Okara, Lindy) are not yet healthcare-specialized — most teams build their own workflow on Claude with explicit guardrails. Don't put PHI into general LLMs without a BAA. Don't auto-publish AI-generated content. Beyond those guardrails, the throughput gains are real.
Three constraints that change every AI CMO workflow:
1. HIPAA. Patient health information (PHI) cannot flow through systems without a Business Associate Agreement (BAA). Most general LLM APIs don't offer BAAs at the consumer tier. Claude Enterprise, Azure OpenAI, and a few others do.
2. FDA promotional rules. Anything that promotes a regulated product (devices, drugs, certain services) is subject to FDA promotional standards. AI-generated content needs review against these.
3. Off-label discussions. AI tools trained on medical literature will often mention off-label uses. For regulated companies, this is a compliance liability if it ends up in customer-facing material.
Internal-facing work is largely safe:
• Competitive research and analysis
• Internal strategy docs
• Campaign brief generation (with no PHI)
• Performance reporting (with anonymized data)
• Content outlines for human writers to develop
• ICP refinement based on aggregate, non-PHI data
• Sales enablement content for internal use
For these use cases, healthcare teams use the same AI CMO tools as any other vertical with minimal additional friction.
Customer-facing content can use AI CMO tooling as long as a compliance review layer exists:
• Marketing emails (drafted by AI, reviewed by compliance, then sent)
• Blog posts (same)
• Landing page copy
• Sales enablement materials
• Conference content
• Webinar scripts
The pattern: AI produces the first draft at 5-10× human speed. Compliance reviewer (often internal regulatory affairs or external counsel for the riskier categories) approves before publication. Total cycle time is faster than human-only, with the same compliance posture.
Three categories to avoid:
1. Anything involving PHI in non-BAA tools. If your data includes patient information, it cannot flow through Claude Pro, ChatGPT Plus, or most consumer-tier LLMs.
2. Auto-publishing customer-facing content. The compliance review step is non-negotiable. Don't let AI publish directly to your website or social channels.
3. Off-label discussions in AI-drafted content without explicit guardrails. Tell the AI explicitly what's on-label and approved for promotional discussion.
Recommended stack as of May 2026:
• Claude Enterprise (with BAA) as the foundation model. Handles PHI under a signed BAA.
• Custom Claude Projects with company-specific guardrails: approved indications, on-label language, brand voice, compliance rules. Build once, use across the team.
• Compliance review workflow embedded in your content production process. Could be a simple Google Doc approval flow or a more structured platform.
• Marketing automation (HubSpot, Veeva) for actual delivery to customers.
Avoid: consumer-tier LLM products for PHI work, AI products that auto-publish without review, vendors who can't sign a BAA.
The throughput gains in healthcare marketing are real but smaller than in other verticals — because the compliance review step caps how fast content can ship. Expect 2-3× throughput gains rather than the 5-10× possible in unregulated categories. The math still works: a healthcare marketing team of 5 producing 3× the content at the same compliance quality is genuinely transformative. Just don't expect the marketing pages of AI CMO vendors to translate directly.
Different healthcare segments have different AI CMO use cases:
• Provider-facing (B2B sales to hospitals/health systems): AI shines on competitive research, account-based content, sales enablement. Less HIPAA concern at the marketing layer.
• Patient-facing (DTC consumer health): Heavy on content production with compliance review. HIPAA concern if any user data flows in.
• Pharma/device: Highest regulatory scrutiny. AI usage limited to internal work and reviewed-before-publication external content.
• Healthcare SaaS/services: Closest to standard B2B SaaS — most AI CMO tooling applies with standard configuration.